MCID: SYP003
MIFTS: 59

Syphilis

Categories: Bone diseases, Fetal diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Syphilis

Summaries for Syphilis

MedlinePlus : 42 Syphilis is a sexually transmitted disease caused by bacteria. It infects the genital area, lips, mouth, or anus of both men and women. You usually get syphilis from sexual contact with someone who has it. It can also pass from mother to baby during pregnancy. The early stage of syphilis usually causes a single, small, painless sore. Sometimes it causes swelling in nearby lymph nodes. If you do not treat it, syphilis usually causes a non-itchy skin rash, often on your hands and feet. Many people do not notice symptoms for years. Symptoms can go away and come back. The sores caused by syphilis make it easier to get or give someone HIV during sex. If you are pregnant, syphilis can cause complications, or you could lose your baby. In rare cases, syphilis causes serious health problems and even death. Syphilis is easy to cure with antibiotics if you catch it early. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading syphilis. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. Centers for Disease Control and Prevention

MalaCards based summary : Syphilis, also known as chancre, is related to late congenital syphilis and cardiovascular syphilis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Syphilis is APOH (Apolipoprotein H), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Cytokine Signaling in Immune system. The drugs Estradiol and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A primary bacterial infectious disease that is a sexually transmitted systemic disease, has material basis in Treponema pallidum subsp pallidum, which is transmitted by sexual contact, transmitted by blood product transfusion, transmitted by congenital method from mother to fetus or transmitted by contact with infectious lesions. If left untreated, produces chancres, rashes, and systemic lesions in a clinical course with three stages continued over many years.

CDC : 3 Syphilis is a sexually transmitted infection that can cause serious health problems if it is not treated. Syphilis is divided into stages (primary, secondary, latent, and tertiary). There are different signs and symptoms associated with each stage.

Wikipedia : 74 Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum subspecies... more...

Related Diseases for Syphilis

Diseases in the Syphilis family:

Early Congenital Syphilis Late Congenital Syphilis
Primary Syphilis Secondary Syphilis
Congenital Syphilis

Diseases related to Syphilis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1011)
# Related Disease Score Top Affiliating Genes
1 late congenital syphilis 34.6 DDX41 CRP CD40LG
2 cardiovascular syphilis 34.6 TPR DDX41
3 early congenital syphilis 34.3 TPR MYH9 CRP CD40LG
4 congenital syphilis 34.3 TPR MYH9 DDX41 CD79A CD40LG CD4
5 latent syphilis 34.1 TPR MYH9 DDX41 CD40LG CD4
6 primary syphilis 34.1 TPR MYH9 DDX41 CD40LG CD4
7 asymptomatic neurosyphilis 33.8 MYH9 CD40LG CD4
8 tertiary syphilis 33.4 TPR MYH9 DDX41 CRP CD8A CD40LG
9 secondary syphilis 33.2 TPR MYH9 FN1 DDX41 CD8A CD79A
10 tertiary neurosyphilis 33.1 TPR MYH9 DDX41 CD40LG CD4
11 syphilitic meningitis 32.9 CD8A CD40LG CD4
12 tabes dorsalis 32.7 MYH9 DDX41 CD4
13 yaws 31.6 TPR MYH9 CD40LG
14 chlamydia 31.6 IL17A CRP CD79A CD40LG
15 toxoplasmosis 31.4 CD79A CD40LG CCR5
16 rubella 31.3 HLA-DRB1 HLA-C CD40LG
17 aortitis 31.2 IL17A CRP CD40LG
18 vasculitis 31.1 IL17A CRP CD79A CD40LG APOH
19 lyme disease 31.1 IL17A HLA-DRB1 CRP CD40LG
20 immune deficiency disease 31.1 FAS CD79A CD40LG CD4 CD209 CCR5
21 keratitis, hereditary 31.1 IL17A CD8A CD4
22 chancroid 31.0 CD40LG CD4 CCR5
23 optic neuritis 31.0 HLA-DRB1 CCR5 CAT
24 human immunodeficiency virus type 1 31.0 HLA-C CD4 CD209 CCR5 B2M
25 meningitis 31.0 IL17A CRP CD40LG CAT
26 exanthem 30.9 CRP CD8A CD40LG CD4 ACE
27 urethritis 30.9 CRP CD40LG CD4
28 retinal vasculitis 30.9 CD40LG APOH ACE
29 myelitis 30.9 IL17A CD40LG APOH
30 trichomoniasis 30.9 CD40LG CD4 CCR5
31 leprosy 3 30.9 IL17A HLA-DRB1 CD8A CD40LG CD4 CD209
32 membranous nephropathy 30.9 CD79A B2M ACE
33 neuroretinitis 30.9 CRP CD40LG CD4 ACE
34 viral hepatitis 30.9 HLA-DRB1 FAS CRP CP CD40LG
35 leptospirosis 30.8 HLA-DRB1 CRP CD40LG
36 optic papillitis 30.8 CRP CD40LG CD4 ACE
37 iridocyclitis 30.8 IL17A CRP CD40LG CD4 ACE
38 pulmonary tuberculosis 30.7 IL17A HLA-DRB1 CRP CAT
39 pityriasis rosea 30.7 HLA-DRB1 HLA-C CD40LG CD4
40 orchitis 30.7 CRP CD8A CD40LG CD4
41 chorioretinitis 30.7 IL17A CD8A CD40LG CD4 ACE
42 antiphospholipid syndrome 30.7 CRP CD40LG APOH
43 glomerulonephritis 30.7 MYH9 FN1 CD79A CD40LG B2M ACE
44 brucellosis 30.7 IL17A CRP CD40LG CAT
45 typhoid fever 30.6 HLA-DRB1 CRP CD40LG
46 choroiditis 30.6 CD40LG CD4 ACE
47 rheumatic disease 30.6 HLA-DRB1 CRP CD40LG APOH
48 acquired immunodeficiency syndrome 30.6 CRP CD79A CD40LG CD4 CCR5 B2M
49 vaginal discharge 30.6 CRP CD40LG CD4
50 human immunodeficiency virus infectious disease 30.6 FAS CD8A CD79A CD4 CD209 CCR5

Comorbidity relations with Syphilis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Schizophreniform Disorder

Graphical network of the top 20 diseases related to Syphilis:



Diseases related to Syphilis

Symptoms & Phenotypes for Syphilis

UMLS symptoms related to Syphilis:


fever, pruritus, pelvic pain, syphilitic chancre, gummatous inflammation

MGI Mouse Phenotypes related to Syphilis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 B2M CAT CCR5 CD4 CD40LG CD79A
2 hematopoietic system MP:0005397 10.1 ACE B2M CCR5 CD4 CD40LG CD79A
3 homeostasis/metabolism MP:0005376 10.1 ACE APOH B2M CAT CCR5 CD4
4 immune system MP:0005387 9.97 ACE B2M CCR5 CD4 CD40LG CD79A
5 mortality/aging MP:0010768 9.83 ACE APOH B2M CAT CCR5 CD4
6 neoplasm MP:0002006 9.17 ACE B2M CAT CCR5 CD79A FAS

Drugs & Therapeutics for Syphilis

Drugs for Syphilis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
2
Polyestradiol phosphate Approved Phase 4 28014-46-2
3
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
4
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
5
Azithromycin Approved Phase 4 83905-01-5 55185 447043
6
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
7
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Hormone Antagonists Phase 4
10 Estradiol 17 beta-cypionate Phase 4
11 Androgen Antagonists Phase 4
12 Estradiol 3-benzoate Phase 4
13 penicillins Phase 4
14 Penicillin G Benzathine Phase 4
15 Penicillin G Procaine Phase 4
16 Antiviral Agents Phase 4
17 Reverse Transcriptase Inhibitors Phase 4
18 Anti-HIV Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Anti-Infective Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Antiprotozoal Agents Phase 4
23 Antimalarials Phase 4
24
Methadone Approved Phase 3 76-99-3 4095
25
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
26
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
27
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
28 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
29
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
32
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
33
Nitrofurantoin Approved, Vet_approved Phase 3 67-20-9 5353830
34
Procaine Approved, Investigational, Vet_approved Phase 3 59-46-1 4914
35
carbamide peroxide Approved Phase 3 124-43-6
36
Acyclovir Approved Phase 3 59277-89-3 2022
37
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
38
Metronidazole Approved Phase 3 443-48-1 4173
39
leucovorin Approved Phase 3 58-05-9 6006 143
40
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
41
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
42
acetic acid Approved Phase 3 64-19-7 176
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
44
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
45
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
46
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
47 Antibiotics, Antitubercular Phase 3
48 Narcotics Phase 3
49 Respiratory System Agents Phase 3
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Syphilis Response to Higher Penicillin Dosage in HIV Co-Infected Patients Completed NCT02611765 Phase 4 Benzathine penicillin G intramuscular 7.2 million units;Benzathine penicillin G intramuscular 2.4 million units
2 Gender-Affirmative Medical Care to Improve HIV Treatment Cascade Among Transgender Women Completed NCT03757117 Phase 4 Feminizing hormone therapy
3 Doctor of Medicine Recruiting NCT02857959 Phase 4 Benzathine Penicillin G
4 The Association Between Molecular Typing of Treponema Pallidum and Treatment Efficacy and Clinical Findings Recruiting NCT02871505 Phase 4 Benzathine Penicillin G
5 A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose Versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects With or Without HIV Infection Recruiting NCT03637660 Phase 4 Benzathine Penicillin
6 Randomized, Clinical Trial to Compare the Serological Response Rates of Serofast Early Syphilis Cases Retreated With Three Doses Benzathine Penicillin and Absence of Any Retreatment Recruiting NCT02884115 Phase 4 benzathine penicillin
7 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection: an Open-label Randomized Clinical Trial Recruiting NCT03854630 Phase 4 Engerix-B
8 Use of Tenofovir/Emtricitabine With Immediate or Deferred Doxycycline 100mg PO Daily for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative Men Who Have Sex With Men: a Pilot Study of Dual Daily HIV and Syphilis PrEP. (The DuDHS Trial). Active, not recruiting NCT02844634 Phase 4 Doxycycline 100mg PO daily x 12 months;Tenofovir/emtricitabine 200/300mg PO daily;Doxycycline 100mg PO daily x 6 months
9 Delivering PrEP in Pregnancy Active, not recruiting NCT03070600 Phase 4 Universal PrEP Counseling;Targeted PrEP Counseling
10 Defining the Best Distribution Strategy of Azithromycin for Yaws Eradication (The Yaws 3 Trial) Active, not recruiting NCT03490123 Phase 4 R1-Total community treatment with azithromycin;R2-Total community treatment with azithromycin;R3-Total community treatment with azithromycin;R2-Total targeted treatment with azithromycin;R3-Total targeted treatment with azithromycin
11 A Randomized, Placebo-controlled Trial of Oral Doxycycline for the Prevention of Syphilis in HIV-positive Men Who Have Sex With Men (MSM) Not yet recruiting NCT02864550 Phase 4 Doxycycline
12 Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men Not yet recruiting NCT03980223 Phase 4 Doxycycline Hyclate Delayed-Release 200 mg
13 PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis Not yet recruiting NCT04050540 Phase 4 Doxycycline
14 Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in COLOMBIA Unknown status NCT02454816 Phase 2, Phase 3
15 A COMMUNITY-BASED, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF COMPREHENSIVE HIV/STIs INTERVENTION AMONG MEN WHO HAVE SEX WITH MEN IN 8 CITIES IN CHINA Unknown status NCT01068015 Phase 3
16 A Randomized Community Intervention Trial on Reducing HIV Infection Among Drug Users Attending Methadone Maintenance Treatment(MMT) and Preventing Secondary Transmission From HIV Positive Clients to Their Sexual Partners in China Unknown status NCT01108614 Phase 3
17 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
18 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
19 Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh Unknown status NCT01572532 Phase 3
20 A Phase III Equivalence Trial of Azithromycin vs. Benzathine Penicillin for the Treatment of Early Syphilis Completed NCT00031499 Phase 3 Azithromycin;Benzathine Penicillin;Doxycycline
21 Single-dose Azithromycin Versus Penicillin G Benzathine for the Treatment of Yaws in Children Completed NCT01382004 Phase 3 Penicillin-G-benzathine;Azithromycin
22 Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda Completed NCT00425984 Phase 3
23 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals Completed NCT00076232 Phase 3 Acyclovir;Acyclovir placebo
24 Strategies for the Prevention of HIV Infection and the Enhancement of Reproductive Health Among Adolescents in Rural Tanzania: MEMA Kwa Vijana Trial Completed NCT00248469 Phase 3
25 Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa Completed NCT00164424 Phase 2, Phase 3 Acyclovir
26 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Recruiting NCT03737669 Phase 3
27 Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and Antiretroviral Treatment Coverage, to Achieve the Virtual Elimination of HIV Transmission by 2020: a NSW HIV Strategy Implementation Project Active, not recruiting NCT02870790 Phase 3 TDF/FTC
28 A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial Active, not recruiting NCT02628886 Phase 3
29 Effects of Metronidazole Plus Intermittent Preventive Treatment of Malaria in Pregnancy on Birth Outcomes: a Randomised Controlled Trial in Zambia Not yet recruiting NCT04189744 Phase 3 IPTp-sulphadoxine-pyrimethamine plus metronidazole;IPTp-dihydroartemisinin-piperaquine plus metronidazole;IPTp-sulphadoxine-pyrimethamine
30 A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia Terminated NCT00529464 Phase 3
31 Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome Unknown status NCT02423421 Phase 2
32 HoMBReS: A Lay Health Advisor Approach to Sexually Transmitted Disease Prevention Completed NCT00207506 Phase 1, Phase 2
33 Computer-assisted STD Partner Notification Completed NCT00207571 Phase 1, Phase 2
34 A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide Completed NCT00213031 Phase 2 Carraguard (PC-515)
35 Development of a Methamphetamine Early Intervention Completed NCT01174654 Phase 1, Phase 2
36 A Randomized Controlled Clinical Trial of an Internet-based Prevention Intervention to Reduce STI in High-risk HIV Infected MSM Completed NCT01198418 Phase 1, Phase 2
37 A Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing STI/HIV Transmission Completed NCT00213018 Phase 2 Carraguard (PC-515)
38 Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM Completed NCT00856323 Phase 2 Truvada
39 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
40 Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212) Completed NCT00158483 Phase 2 Acyclovir (ACV)
41 Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection: an Open-label Randomized Clinical Trial Completed NCT02148601 Phase 2 Standard Antibiotic Therapy;Vancomycin (before randomization)
42 Couples Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan Completed NCT01690442 Phase 2
43 Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis Completed NCT02750059 Phase 2 TDF/3TC/EFV + Telmisartan;TDF/3TC/EFV only
44 Randomized Clinical Trial: Single Versus Multiple-infusion Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection Completed NCT03427229 Phase 2 Vancomycin (before randomization)
45 Phase II Pilot Study to Estimate the Adverse Events Associated With the Lock Solution When Used to Salvage Central Venous Catheter (CVC) in the Setting of a Central Line Associated Bloodstream Infection (CLABSI) Completed NCT01539343 Phase 2 Antimicrobial Solution
46 A Brief, Clinic-Based, Safer Sex Program for Young African-American Men Completed NCT01439503 Phase 2
47 Intra-articular Injections of Platelet-rich Plasma in Patients With Knee Pain of Articular Cartilage Origin (Degenerative Chondropathy and Early OA). Completed NCT01747018 Phase 1, Phase 2
48 AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION Completed NCT01710553 Phase 2
49 AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN GSK 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION Completed NCT01710540 Phase 2
50 AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION Completed NCT01710527 Phase 2 Metformin 500mg;Glucophage 500mg

Search NIH Clinical Center for Syphilis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR

Cochrane evidence based reviews: chancre

Genetic Tests for Syphilis

Anatomical Context for Syphilis

MalaCards organs/tissues related to Syphilis:

40
Testes, Skin, Bone, Liver, Lung, Heart, Eye

Publications for Syphilis

Articles related to Syphilis:

(show top 50) (show all 24390)
# Title Authors PMID Year
1
The Relationship Between Herpes Zoster, Syphilis and Chickenpox. 61 42
31688874 2019
2
Differences between congenital-syphilis presenting as sepsis and neonatal sepsis: A case-control study. 61 42
31689826 2019
3
Neurosyphilis complicated with pial arteriovenous fistula: A rare case report. 42
31702628 2019
4
Antiphospholipid antibodies, antiphospholipid syndrome and infections. 54 61
18295729 2008
5
[Antiphospholipid syndrome: pathophysiology and clinicobiological aspects]. 54 61
19469420 2008
6
Intrathecal antitreponemal antibody synthesis determination using the INNO-LIA Syphilis Score. 54 61
18204743 2007
7
Effect of genital ulcer disease on HIV-1 coreceptor expression in the female genital tract. 54 61
18008231 2007
8
Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. 54 61
17299719 2007
9
Hysteroscopy in the evaluation of patients with recurrent pregnancy loss: a cohort study in a primary care population. 54 61
15809790 2004
10
Factor V Leiden mutation in Sneddon syndrome. 54 61
12765305 2003
11
Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. 54 61
12209489 2002
12
Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. 54 61
11491498 2001
13
Antiphospholipid antibody syndrome. A literature review. 54 61
11367816 2001
14
Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. 54 61
10554081 1999
15
[The antiphospholipid syndrome--yesterday, today, tomorrow]. 54 61
9623352 1998
16
Antiphospholipid antibodies: guidelines for determination. 54 61
19078229 1997
17
[The incidence of the antiphospholipid syndrome in the clinical and biological manifestations of systemic lupus erythematosus]. 54 61
9424663 1997
18
Update: antiphospholipid antibodies. 54 61
19078201 1997
19
Antibodies to beta2-glycoprotein I--a specific marker for the antiphospholipid syndrome. 54 61
9276526 1997
20
Lupus anticoagulants: diagnostic dilemma and clinical challenge. 54 61
10169622 1997
21
Autoantibodies to phospholipids and to the coagulation proteins in AIDS. 54 61
9184392 1997
22
Prevalence and clinical significance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. 54 61
9142046 1997
23
Antiphospholipid antibodies and atherosclerosis. 54 61
8902778 1996
24
Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. 54 61
8725711 1996
25
Anticardiolipin antibodies from syphilis and systemic lupus erythematosus induce leakage in cardiolipin vesicles. 54 61
8736113 1996
26
Prevalence of antiphospholipid antibodies in patients with ankylosing spondylitis. 54 61
8991987 1995
27
Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. 54 61
8991988 1995
28
Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. 54 61
7667838 1995
29
[A case of systemic lupus erythematosus associated with severe fibrinoid necrosis located mainly in the glomerular afferent arteriole]. 54 61
7699957 1995
30
Presence of multiple anti-phospholipid antibody specificities in a pediatric population. 54 61
8679908 1995
31
[Middle cerebral artery occlusion with unilateral moyamoya like vessels and with ruptured anterior cerebral artery aneurysm--its relation to the antiphospholipid antibody syndrome]. 54 61
7826715 1994
32
Differences in functional activity of anticardiolipin antibodies from patients with syphilis and those with antiphospholipid syndrome. 54 61
8063429 1994
33
Association of antimitochondrial antibodies type 5 and anti-beta 2 glycoprotein I antibodies in the antiphospholipid syndrome. 54 61
7799349 1994
34
Clinical and therapeutic aspects associated to phospholipid binding antibodies (lupus anticoagulant and anticardiolipin antibodies). 54 61
7988946 1994
35
[Primary antiphospholipid syndrome: clinical and biological study of 36 cases]. 54 61
8189783 1994
36
Postpartum myocardial infarction in a patient with antiphospholipid syndrome. 54 61
8155200 1994
37
Distinguishing beta 2-glycoprotein I dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. 54 61
7918046 1993
38
High prevalence of anti-cardiolipin antibody, C1q-, C3d-, and mRF-IgG immune complexes, and anti-nuclear antibody in hemophiliacs irrespective of infection with human immunodeficiency virus type 1. 54 61
8410668 1993
39
Lupoid sclerosis with antiphospholipid and antimyelin antibodies. 54 61
8496878 1993
40
Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. 54 61
1522218 1992
41
Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. 54 61
1602135 1992
42
Antiphospholipid antibody syndrome: a case report and review of the literature. 54 61
1801188 1991
43
[Anticardiolipin antibodies in diffuse connective tissue diseases with IgG, IgM and IgA isotypes]. 54 61
2267732 1990
44
Vasculopathy associated with the antiphospholipid antibody syndrome. 54 61
2189163 1990
45
Biological true and false serological tests for syphilis: their relationship with anticardiolipin antibodies. 54 61
2340925 1990
46
Antinuclear antibodies in infectious diseases. 61
31718355 2020
47
Diterpenoids with inhibitory activity of nitrite production from Croton floribundus. 61
31639485 2020
48
Effects of mobile health on HIV risk reduction for men who have sex with men. 61
31558040 2020
49
County-Level Social Capital and Bacterial Sexually Transmitted Infections in the United States. 61
31842088 2020
50
Detection-Based Monetary Incentives to Improve Syphilis Screening Uptake: Results of a Pilot Intervention in a High Transmission Setting in Southern China. 61
31842086 2020

Variations for Syphilis

Copy number variations for Syphilis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 111152 17 35097918 35138441 Copy number ERBB2 Syphilis

Expression for Syphilis

Search GEO for disease gene expression data for Syphilis.

Pathways for Syphilis

Pathways related to Syphilis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 HLA-DRB1 HLA-C CD8A CD79A CD40LG CD4
2
Show member pathways
13.17 TPR IL17A HLA-DRB1 HLA-C FN1 CD40LG
3
Show member pathways
13.12 TPR MYH9 IL17A HLA-DRB1 HLA-C FN1
4
Show member pathways
12.67 HLA-DRB1 HLA-C FAS CD209 B2M
5
Show member pathways
12.45 IL17A FAS CD8A CD40LG CD4 CCR5
6 12.36 IL17A FAS CD8A CD79A CD40LG B2M
7
Show member pathways
12.3 IL17A HLA-DRB1 HLA-C FAS CD8A CD40LG
8 12.17 HLA-DRB1 HLA-C CD4 B2M
9 11.93 HLA-C CD8A CD40LG B2M
10 11.89 HLA-DRB1 HLA-C CD8A CD40LG CD4
11 11.84 CD8A CD79A CD4 CD209
12
Show member pathways
11.79 HLA-DRB1 CD8A CD4 B2M
13
Show member pathways
11.71 HLA-DRB1 CD8A CD4 CCR5 B2M
14 11.64 IL17A CD8A CD4
15 11.59 CD8A CD4 CD209
16 11.56 HLA-DRB1 CD8A CD4
17 11.04 CD8A CD79A CD40LG CD4

GO Terms for Syphilis

Cellular components related to Syphilis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.17 MYH9 HLA-DRB1 HLA-C FAS CP CD8A
2 extracellular space GO:0005615 10.02 IL17A FN1 CRP CP CD40LG CAT
3 extracellular exosome GO:0070062 9.96 MYH9 HLA-DRB1 HLA-C FN1 FAS CP
4 extracellular region GO:0005576 9.93 IL17A FN1 FAS CRP CP CD8A
5 cell surface GO:0009986 9.61 HLA-DRB1 HLA-C FAS CD40LG CD4 CD209
6 ER to Golgi transport vesicle membrane GO:0012507 9.58 HLA-DRB1 HLA-C B2M
7 MHC class I protein complex GO:0042612 9.43 HLA-C B2M
8 external side of plasma membrane GO:0009897 9.28 IL17A HLA-DRB1 CD8A CD79A CD40LG CD4

Biological processes related to Syphilis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.89 TPR HLA-DRB1 CD4 CD209 CCR5
2 cell surface receptor signaling pathway GO:0007166 9.81 CD8A CD79A CD4 CCR5
3 regulation of immune response GO:0050776 9.78 HLA-C CD8A CD40LG B2M
4 protein homotetramerization GO:0051289 9.7 CD79A CAT B2M
5 immune system process GO:0002376 9.7 HLA-DRB1 HLA-C CD8A CD79A CD4 CD209
6 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-DRB1 HLA-C B2M
7 positive regulation of T cell proliferation GO:0042102 9.58 CD40LG CD4 CD209
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.43 HLA-C B2M
9 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.43 HLA-C B2M ACE
10 fusion of virus membrane with host plasma membrane GO:0019064 9.37 CD4 CCR5
11 entry into host cell GO:0030260 9.32 CD4 CCR5
12 immune response GO:0006955 9.28 IL17A HLA-DRB1 HLA-C FAS CD8A CD40LG
13 antigen processing and presentation GO:0019882 9.26 HLA-DRB1 HLA-C CD8A CD209

Molecular functions related to Syphilis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 TPR MYH9 CD79A CD4 CAT B2M
2 identical protein binding GO:0042802 9.8 FN1 FAS CRP CD4 CAT B2M
3 virion binding GO:0046790 9.37 CRP CD209
4 coreceptor activity GO:0015026 9.33 CD8A CD4 CCR5
5 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-C CD209
6 virus receptor activity GO:0001618 8.92 HLA-DRB1 CD4 CD209 CCR5

Sources for Syphilis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....